Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
AVGO has slipped back to $357.31, down nearly 5% on the week, widening the already striking gap between where the stock trades and where analysts think it belongs.
The Street's mean price target is $528, implying roughly 48% upside from current levels. That gap has been a persistent feature of the AVGO story across recent notes, but it is harder to dismiss this week given the direction of travel. All the analyst activity in the data follows the September 3 earnings print, when a sell-the-news reaction knocked the stock about 3.4% on the day. The response from the Street was almost uniformly constructive. Morgan Stanley nudged its target to $505, Citigroup raised to $515 while keeping its Buy, Raymond James lifted to $475, and Macquarie upgraded outright to Outperform. DA Davidson was the notable outlier, cutting its target from $400 to $350, putting it close to the current price. The bull case centres on AI custom silicon growing 261% year-on-year in the last quarter to $12.2 billion, with management guiding AI semiconductor revenue to $115 billion in FY27 and $230 billion in FY28. The bear case argues those numbers were already embedded in expectations, and that non-AI semiconductor revenue and infrastructure software both missed. With the next print not until December 10, the market has nearly two months to keep debating which camp is right.
The lending market provides no directional signal. Short interest has edged up about 7.6% on the week to 1.2% of the free float, a move that sounds meaningful in percentage terms but leaves the absolute level too low to matter. Borrow costs are negligible at 0.28%, down from a month ago. Availability is essentially unlimited, with no constraint in the lending pool whatsoever. Options positioning is similarly unhelpful as a directional read: the put/call ratio at 0.99 is fractionally below its 20-day average of 0.99 and well inside the 52-week range. The lending and options picture is, in short, inert.
The more interesting flow data comes from the ownership register. Co-founder and director Henry Samueli sold approximately $90 million in shares on September 23, all under a pre-arranged 10b5-1 plan. Pre-planned sales are a weaker signal than discretionary ones, and Samueli's institutional-scale holding of roughly 48 million shares means the reduction is proportionally modest. Still, the 90-day insider net across all trades is negative by around $280 million, which the register confirms is driven almost entirely by Samueli's programme. On the institutional side, BlackRock added 12.3 million shares in the quarter to September, Capital Research added 4.8 million, and FMR added 20.2 million, the largest of the three moves. The index-fund flows are directionally positive but reflect index-weight mechanics as much as conviction.
Peer performance this week underscores that weakness in AVGO is not company-specific. ARM fell 15.6% on the week. CEVA dropped 14.7%. IFX lost 13.4%. Against that backdrop, Broadcom's 5% decline looks relatively contained, though it still erases most of last week's 6% gain.
The ORTEX alt data adds one note worth filing: retail attention has been running well below its own 90-day average, with a Wikipedia views z-score of negative 1.75. That is attention, not a revenue signal, but it suggests the Hock Tan headlines from last week have not pulled in a new wave of retail interest at these price levels.
With December 10 now 57 days away, the question sharpening is whether the stock can narrow the discount to consensus before the print, or whether the pattern from September 3, strong results met with selling, repeats.
See the live data behind this article on ORTEX.
Open AVGO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
